Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), the nano cap company, popped up by nearly 19% yesterday continuing the rally that started first on December 4 when the company announced the clearance from the FDA for Microsyn Scar Management Hydrogel. The company recently announced the appointment of Russell Harrison as one of its board of directors. For the year 2014 and 2015, the analyst estimate of loss for Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) is kept at $0.51 per share on revenues of $14.2 million and $0.48 per share on $15.2 million revenues. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) shares after opening at $4.95 moved to $5.20 on last trade day and at the end of the day closed at $4.79. Company price to sales ratio in past twelve months was calculated as 2.31 and price to cash ratio as 9.59. Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) showed a negative weekly performance of -15.37%.
Bovie Medical Corporation (NYSEMKT:BVX), which is a manufacturer as well as a marketer of electrosurgical products, soared by nearly 15% on Tuesday. It has recently announced the date of issuing its financial results and other corporate developments. The company has planned the release of fourth quarter and full year 2013 results on Monday, March 31, 2014. Bovie Medical Corporation (NYSEMKT:BVX) shares fell -3.32% in last trading session and ended the day on $3.78. BVX return on equity ratio is recorded as -8.60 % and its return on assets is -6.80%. Bovie Medical Corporation (NYSEMKT:BVX) yearly performance is 5.29%.
Laboratory Corporation of AmericaHoldings (NYSE:LH) announced the appointment of Glenn A. Eisenberg as Executive Vice President and Chief Financial Officer, effective June 16, 2014. Brad Hayes will continue in his role as Chief Financial Officer through the transition to Mr. Eisenberg. Laboratory Corp. of America Holdings (NYSE:LH) shares moved up 4.15% in last trading session and was closed at $98.64 while trading in range of $97.50 – $102.00 – Laboratory Corp. of America Holdings (NYSE:LH)year to date (YTD) performance is 7.96%.
Analysts at HC Wainwright upped their price objective on shares of Insmed (NASDAQ:INSM) from $25.00 to $30.00 in a research report issued to clients and investors on Wednesday, Stock Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Insmed Incorporated (NASDAQ:INSM) weekly performance is -15.94%. On last trading day company shares ended up $15.90. Insmed Incorporated (NASDAQ:INSM) distance from 50-day simple moving average (SMA50) is -17.28%. Analysts mean target price for the company is $26.43.
Leave a Reply